January 13 - 17, 2014
Renaissance Hotel and Palm Springs Convention Center Palm Springs, California

A Community Dedicated to the
Evolving Field and Future of Biotherapeutics
Archived Content

Pipeline 4 Header 

Inaugural
Fine-Tuning Expression in CHO
Turning the Work Horse Into a Race Horse
January 23-24 
 

  

  

Day 1| Day 2 | Download Pipeline 4 Brochure 

THURSDAY, JANUARY 24

7:15 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee

 

Automation, Analysis and the Future of CHO 

8:15 Chairperson’s Remarks

Natalia Gomez, Ph.D., Scientist II and Group Leader, Cell Culture Process Development, Process Sciences, Agensys, Inc.

8:20 A High-Throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics

Shuangping Shi, Ph.D., Principal Scientist, Bioprocess Development, Merck Research Laboratory, Merck & Co., Inc.

We report here an integrated high-throughput and automated platform for development of manufacturing cell lines for the production of protein therapeutics. This integrated approach has been used to generate high-producing Chinese hamster ovary (CHO) cell lines for the production of therapeutic monoclonal antibody (mAb) as well as their fusion proteins. This automated platform demonstrated advantages of significantly increased capacity, ensured clonality, and traceability in cell line history with electronic documentation.

8:50 Simplifying a Cell Culture Platform Process Using Automated Micro-Scale Bioreactors

Natalia Gomez, Ph.D., Scientist II and Group Leader, Cell Culture Process Development, Process Sciences, Agensys, Inc.

During process development for Phase I programs, using platform cell culture conditions is preferred. This platform process should support good productivity and be straightforward to execute in GMP manufacturing. In this study, we focused on simplification of an existing complex platform process. For this, we investigated the performance of 17 CHO cell lines in 15mL automated micro-bioreactors using a simplified cell culture process.

9:20 Analysis of Glycosylation in CHO Cells through Interpretation of Mass Spectrometry Data Using Mathematical Modeling

Sandra V. Bennun, Ph.D., MSc, Researcher, Sandia National Laboratories

Because the therapeutic quality of commercial glycoproteins is affected by glycosylation, manufacturers are increasingly becoming focused on controlling the glycoform distribution of their products. To assist in this process, we demonstrate a model that extracts structural details from MALDI-TOF mass spectrometry data to predict enzyme activity profiles, glycan distributions and abundances in ten CHO cell lines.

Selexis9:50 SURE CHO-Mplus – Selexis’ Next Generation Cell Lines for Overcoming Expression BottlenecksIgor Fisch, Ph.D., CEO & Chairman of the Board, Selexis SAWith certain proteins, optimal productivity cannot be achieved solely by elevated transcription. The secretory pathway needs to be modified to adjust for the increased load. The Selexis SURE CHO-Mplus panel of modified cell lines addresses different secretory bottlenecks and provides a powerful tool for optimizing expression of difficult-to-express proteins.

10:05 Coffee Break in the Exhibit Hall with Poster Awards

10:45 Batch, Fed-Batch, and Microcarrier Cultures with CHO Cell Lines in a Pressure-Cycle Driven Miniaturized Bioreactor

Beum Jun Kim, Ph.D., Research Associate, Cornell University

We have developed a novel pressure-cycle driven miniaturized bioreactor for the use of mammalian cell cultures to facilitate the process development. We obtained a comparable CHO cell growth and an enhanced target protein production in the miniaturized bioreactor, compared to conventional lab-scale flask cultures. We also applied the system to fed-batch and microcarrier cultures, achieving comparable results to other literature.

11:15 Dynamic Model for CHO Cell Engineering

Kyongbum Lee, Ph.D., Associate Professor and Acting Chair, Department of Chemical & Biological Engineering, Tufts University

Progress in CHO cell fed-batch processes has largely resulted from separate advances in process and cell line development. We use a dynamic model to explore ~104 process and cell modifications. Knockdowns in glycolysis were the most beneficial; however, depending on the process conditions, such knockdowns could reduce the titer. Our results highlight the need to combine process and cell modifications.

11:45 Insights into CHO Cell Metabolism with Comparative Proteomics and Isotopic Metabolic Flux Analysis

John A. Morgan, Ph.D., Associate Professor, School of Chemical Engineering, Purdue University

A CHO cell culture was studied in two different fed-batch process conditions with significantly different lactate secretion profiles. An untargeted proteome analysis was compared with metabolic flux maps determined from 13-C labeling at different time points in the cultures. The results of this correlation analysis will be presented with a focus on the level of control of fluxes based upon enzyme levels.

12:15 pm Close of Morning Session

12:30 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own

1:30 End of Conference



Day 1| Day 2 | Download Pipeline 4 Brochure 

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag 


PTK Event APP 
New this year!
The PepTalk App will allow attendees to browse the agenda, create custom schedules, navigate the exhibit hall and explore poster presentations.

2014 Brochure Cover 

Right Arrow Download the Brochure 

Right Arrow Event at-a Glance 

      Premier Sponsors: 

EMD Millipore 

 Novozymes (white) 

PerkinElmer NEW 2009 

 Protein Simple  

  

Right Arrow View All Sponsors 

Right Arrow View Media Partners 

Add to Outlook Add to Outlook 

Training Seminars 

Mon-Tues, January 13-14 

Biologics Formulation and Delivery  

 


Buzz Sessions
BuzZ Sessions are facilitated, small-group discussions. Interactive participation leads to problem-solving solutions and future collaborations around focused topics.
Click here for BuzZ topics